Drug Profile
Anti-L-selectin monoclonal antibody - Stanford University
Alternative Names: DREG 200 - Stanford UniversityLatest Information Update: 20 Feb 2008
Price :
$50
*
At a glance
- Originator Stanford University School of Medicine
- Class
- Mechanism of Action Advanced glycosylation end product modulators; L-selectin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Type 1 diabetes mellitus
Most Recent Events
- 08 Apr 1999 No-Development-Reported for Type-1 diabetes mellitus in USA (Unknown route)
- 23 Jan 1995 Preclinical development for Type-1 diabetes mellitus in USA (Unknown route)